Results 11 to 20 of about 82,943 (135)

The ChIP-seq-defined networks of Bcl-3 gene binding support its required role in skeletal muscle atrophy [PDF]

, 2012
NF-kappaB transcriptional activation is required for skeletal muscle disuse atrophy. We are continuing to study how the activation of NF-kB regulates the genes that encode the protein products that cause atrophy. Using ChIP-sequencing we found that Bcl-3,
Jackman, Robert W., Kandarian, Susan C., Wu, Chia-Ling   +2 more
core   +12 more sources

Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications [PDF]

, 2012
Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post-translational modifications controlling virtually all cellular processes.
Fulda, Simone, Rajalingam, Krishnaraj, Dikic, Ivan   +2 more
core   +2 more sources

Adenoid cystic carcinoma: emerging role of translocations and gene fusions. [PDF]

, 2016
Adenoid cystic carcinoma (ACC), the second most common salivary gland malignancy, is notorious for poor prognosis, which reflects the propensity of ACC to progress to clinically advanced metastatic disease.
Brait, Mariana, Ha, Patrick K, Izumchenko, Evgeny, Meir, Juliet, Sidransky, David, Wysocki, Piotr T   +5 more
core   +5 more sources

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells [PDF]

, 2015
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons, including acquisition of resistance to gemcitabine, the first-line chemotherapeutic approach.
Bielli, P, Calabretta, S, Capurso, G, DELLE FAVE, Gianfranco, Fendrich, V, Passacantilli, I, Pilozzi, Emanuela, Sette, C.   +7 more
core   +4 more sources

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source

BCL-W has a fundamental role in B cell survival and lymphomagenesis. [PDF]

, 2017
Compromised apoptotic signaling is a prerequisite for tumorigenesis. The design of effective therapies for cancer treatment depends on a comprehensive understanding of the mechanisms that govern cell survival.
Annette S. Kim, Barrett, Christine M. Eischen, Clare M. Adams, Gibson, Haldar, Jerald Z. Gong, John K. Choi, Lee, Placzek, Ramkrishna Mitra, Schmitz, Visco, Wang, Yang   +14 more
core   +2 more sources

Targeting BCL-2 regulated apoptosis in cancer [PDF]

, 2018
The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death ...
Campbell, Kirsteen J., Tait, Stephen W.J.   +1 more
core   +1 more source

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]

, 2016
Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi, A Mai, A Saito, A Vannini, A Villar-Garea, AA Lane, AJ Dembo, AJ Wilson, Albandri Alfraidi, AM Abukhdeir, Aun Muhammad, AW Kurian, B Sorbe, BA Goff, BD Strahl, BH Huang, BY Karlan, C Aghajanian, C Bosetti, C Campas-Moya, C Gomez-Raposo, CJ Dunton, CM Grozinger, CS Marcus, CT Lin, D Khabele, D Matei, D Mottet, D Strumberg, D Waltregny, DC Drummond, DD Bowtell, DE Marsden, DK Armstrong, DM Dinulescu, Dmitri Pchejetski, DO Bauerschlag, E Hu, E Smolle, E Verdin, G Piperno, G Tortolero-Luna, H Naora, HA Risch, Heba Alshaker, HL Cheng, I Cetin, IK Kolasa, J Boyd, J Morrison, J Permuth-Wey, J Plisiecka-Halasa, J Prat, J Sonnemann, J Zhang, JA Rauh-Hain, JE Bolden, JE Palmer, JF Stratton, JH Choi, JJ Hwang, JL Benedet, JL MacDonald, JL Walker, JM Piek, JP Secrist, JR Graff, JR Ribeiro, K Kudoh, K Ozaki, K Sawada, K Struhl, KA Lowe, KB Glaser, Keith Sacco, KF McGonigle, KR Cho, L Dai, Leonardo Monzon, M Booth, M Fung-Kee-Fung, M Kartalou, M Markman, M Ohmichi, M Schuijer, MF Fathalla, MJ Piccart, MJ Scanlan, MK Tuxen, ML Friedlander, MM Leitao, MS Finnin, MS Kim, N Einhorn, N Einhorn, N Takai, N Takai, N Takai, NC Hait, NG Gavalas, NS Bese, P Marks, P Zhu, PH Wang, R Furumai, RA Burger, RA Burger, RC Bast Jr, RF Ozols, RL Coleman, RP Warrell Jr, RP Wernyj, S Gregoire, S Rinaldi, S Senese, S Spiegel, SA Cannistra, SA Gayther, SA Gayther, SC Modesitt, SR Wedge, T Meyer, TJ Herzog, TJ Perren, TL Klug, V Auner, V Conteduca, W Fischle, W Weichert, X Qian, YV Shebzukhov   +130 more
core   +1 more source

Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML [PDF]

, 2002
HTIF1α, a transcription coactivator which is able to mediate RARα activity and functionally interact with PML, is encoded by a gene on chromosome 7q32–34, which is a critical region in acute myeloid leukemias (AML). With the assumption that this gene may
AGUIARI, Gianluca, CASTOLDI, GL, CUNEO, Antonio, DE ANGELI, C, DEL SENNO, Laura, GANDINI, D, LANZA, F, MANZATI, E, PANDOLFI, PP   +8 more
core   +1 more source

Drug target optimization in chronic myeloid leukemia using innovative computational platform. [PDF]

, 2015
Chronic Myeloid Leukemia (CML) represents a paradigm for the wider cancer field. Despite the fact that tyrosine kinase inhibitors have established targeted molecular therapy in CML, patients often face the risk of developing drug resistance, caused by ...
Benque, David, Chuang, Ryan, Cook, Byron, Fisher, Jasmin, Gottgens, Berthold, Hall, Benjamin A, Ishtiaq, Samin, Koschmieder, Steffen, Piterman, Nir, Taylor, Alex, Vardi, Moshe   +10 more
core   +2 more sources